NASDAQ NMS - GLOBAL MARKET · KYMR
+1.04% · +$1.25 · Vol 466.9K
Market closed · last close 4:00 PM ET · price as of 16:00:40 ET
Kymera Therapeutics Inc

Kymera Therapeutics Inc

Biotechnology
$121.05
Card
Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factorsMethodology
KYMR
Kymera Therapeutics Inc
Mon Aug 24 · market closed · Markets closed · resumes Tue 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

53/ 100
Veridion Score
NEUTRAL · HIGH confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Mon Aug 24 · market closed · Markets closed · resumes Tue 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is KYMR moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading KYMR catalysts
About Kymera Therapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2020
Employees
273
Country
US

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$119.98
Day high
$121.56
Day low
$116.46
Previous close
$119.80
52W high
$127.31
-4.92% from high
52W low
$40.69
93% of range
Market cap
$10B
EPS
$-3.3300
Beta
0.78
Shares out
83.2M
Volume
466.9K
0.74× rel vol
Avg volume
627.7K
VWAP
$119.71
Price history computed in-house
1W
-0.27%
1M
+9.48%
3M
+48.16%
1Y
+189.45%
YTD
+55.57%
SMA 50 $109.49 · above
SMA 200 $86.48 · above
52W position 93%

KYMR overview

Veridion Score
53
Registered · 2026-08-24
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around KYMR.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading KYMR Form 4 filings
Public disclosures

Congress activity in KYMR

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for KYMR in the cached public ledger.

Federal contracts

KYMR contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for KYMR in this window.
Lobbying spend

KYMR lobbying filings, year to date.

Registered lobbying filings matched to Kymera Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for KYMR in this window.
Loading news for KYMR
Analyst ratings
Sovereign unlock shows live analyst consensus for KYMR.
Options
Sovereign unlock shows live options positioning for KYMR.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.